Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials - Wikidata - awgldk - TriplyDB

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

http://www.wikidata.org/entity/Q58760132

about

Prognostic utility of serum free light chain ratios and heavy-light chain ratios in multiple myeloma in three PETHEMA/GEM phase III clinical trials

http://www.wikidata.org/entity/Q58760132

description

article publié dans la revue scientifique PLoS ONE

@fr

im Januar 2018 veröffentlichter wissenschaftlicher Artikel

@de

scientific article published in PLoS ONE

@en

wetenschappelijk artikel

@nl

наукова стаття, опублікована у 2018

@uk

name

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@en

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@nl

type

label

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@en

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@nl

prefLabel

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@en

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@nl

P1433

Q58760132-2D61C3A0-C91D-4880-8C82-B2B84FB5452F

P1476

Q58760132-BCFBB28A-70B5-440E-AD0D-8FA245D4317D

P2093

Q58760132-02C043AB-0166-45F8-9F53-8854E1D99DCC

Q58760132-0BD8E2B9-423C-4281-A4DC-766899CD9EA4

Q58760132-14F92FFD-BBE7-46C7-B63C-3F116159B11B

Q58760132-26928F96-B573-4EF3-88D6-11077F9FBBFA

Q58760132-27B45DD7-9C2A-41E5-AF33-6D9CDDE1B553

Q58760132-3B10747D-D50A-4AAC-BA21-152A803D482B

Q58760132-3C07E086-A78E-4268-B5CA-9C5B2938EC94

Q58760132-3F817805-BFA8-41D4-A8E5-67F489FB9887

Q58760132-46DC2F9A-8037-4D6D-94E9-8774FD552F2C

Q58760132-55C1B794-173E-40FF-9077-D3C92B407BC6

P2860

Q58760132-0359506D-1A7A-4AA8-8FEC-A7B0A74C9972

Q58760132-1B314887-26FA-4690-B28C-8364DA5D4E8E

Q58760132-22CB7355-3499-4DB4-BC67-0D0805DFFFFB

Q58760132-2349CBBA-521C-42B0-A012-E238FC24F255

Q58760132-3444FB4D-7A8A-48CF-A846-0709C6E1B1B7

Q58760132-416DDCFC-A1F1-4EE2-8673-72A60BD6A586

Q58760132-45605B39-AE30-411D-8274-8E83C21B78C8

Q58760132-4E23B6D4-5087-436C-8836-CF98B5D6B6AA

Q58760132-601CF6C2-3440-44F8-9576-BBE45CFE031C

Q58760132-67FC9CD7-8180-4545-9817-70408208F304

P304

Q58760132-D3ACD3FC-A7B8-4CB0-8A8C-D62B377D49CC

P31

Q58760132-F2B599E2-93BD-48F7-AB3A-5E00C7B1963C

P356

Q58760132-D8BE13BF-9444-45C0-BD0A-06C8FEB1D239

P407

Q58760132-10A070D6-07EA-4CCE-BBA7-7564B8C203B2

P433

Q58760132-2072D5B4-3EA8-41E9-8951-FE5FFF4CA691

P478

Q58760132-B9FD9300-9141-42E8-A1A5-52CA3B2ED3EF

P50

Q58760132-59316AC6-65A2-42AC-AC0D-22F310F48526

Q58760132-B3A7F62C-C160-4F10-8AE7-D1F8FFBF3A5E

Q58760132-EAFBBE23-0E79-4B70-96DB-67283550A7BD

P577

Q58760132-85B2DEB7-D1C8-42ED-8910-89E867579A94

P698

Q58760132-71C63AF7-0BD8-4CA3-8B78-3EC19FF8A45F

P932

Q58760132-B101BFCF-215E-4F71-9232-C13C8D0A1F56

P356

JOURNAL.PONE.0203392

P1433

P1476

Prognostic utility of serum fr ...... /GEM phase III clinical trials

@en

P2093

Albert Oriol

http://www.w3.org/2001/XMLSchema#string

Ana Isabel Teruel

http://www.w3.org/2001/XMLSchema#string

Ana Lopez de la Guia

http://www.w3.org/2001/XMLSchema#string

Antonio Valeri

http://www.w3.org/2001/XMLSchema#string

Bruno Paiva

http://www.w3.org/2001/XMLSchema#string

Cecilia Cueto-Felgueroso

http://www.w3.org/2001/XMLSchema#string

Enrique Bengoechea

http://www.w3.org/2001/XMLSchema#string

Felipe de Arriba

http://www.w3.org/2001/XMLSchema#string

Francisco Javier Peñalver

http://www.w3.org/2001/XMLSchema#string

GEM (Grupo Español de MM)/PETH ...... ignas) Cooperative Study Group

http://www.w3.org/2001/XMLSchema#string

P2860

Prognostic value of the serum free light chain ratio in newly diagnosed myeloma: proposed incorporation into the international staging system

Serum free light chain ratio is an independent risk factor for progression in monoclonal gammopathy of undetermined significance

High serum-free light chain levels and their rapid reduction in response to therapy define an aggressive multiple myeloma subtype with poor prognosis

A clinical staging system for multiple myeloma. Correlation of measured myeloma cell mass with presenting clinical features, response to treatment, and survival.

International uniform response criteria for multiple myeloma.

Prognostic value of serum free light chain ratio at diagnosis in multiple myeloma.

Utility of serum free light chain measurements in multiple myeloma patients not achieving complete response to therapy.

Immunoglobulin heavy/light chain ratios improve paraprotein detection and monitoring, identify residual disease and correlate with survival in multiple myeloma patients.

Suppression of uninvolved immunoglobulins defined by heavy/light chain pair suppression is a risk factor for progression of MGUS.

Serum free light chains, not urine specimens, should be used to evaluate response in light-chain multiple myeloma

P304

e0203392

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1371/JOURNAL.PONE.0203392

http://www.w3.org/2001/XMLSchema#string

P407

P433

9

http://www.w3.org/2001/XMLSchema#string

P478

13

http://www.w3.org/2001/XMLSchema#string

P50

Ramón García-Sanz

Jesus San Miguel

Lucía López-Anglada

P577

2018-09-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

30192814

http://www.w3.org/2001/XMLSchema#string

P932

6128544

http://www.w3.org/2001/XMLSchema#string